Innovative therapeutics

RSS Feed

Investors

Press Releases

Email Alerts

Jan 24, 2018

BioMarin to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast on Thursday, February 22 at 4:30pm ET

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
Jan 3, 2018

BioMarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the 36th Annual J.P. Morgan Healthcare Conference on
Dec 22, 2017

BioMarin Receives Anticipated Notification of PDUFA Extension for Pegvaliase Biologics License Application (BLA) to May 28, 2018

Regulatory Review Process Proceeding In-line with Company's Expectations

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the Biologics License...
Dec 19, 2017

BioMarin Doses First Patient in Global GENEr8-1 Phase 3 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

Second Phase 3 Study, GENEr8-2, to Begin at the Start of 2018

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has dosed the first patient in the global GENEr8-1 Phase 3 study with the 6e13 vg/kg dose for valoctocogene roxaparvovec...
Dec 11, 2017

BioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 American Society of Hemophilia (ASH) Meeting

New 1.5 Year Results Demonstrating 6e13 vg/kg Dose Achieved Sustained Factor VIII Levels within the Normal Range in Severe Hemophilia A for Most Patients

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced updates on valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy treatment for severe hemophilia at ASH. Efficacy...